NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) has announced that its CEO and Chairman, Prof. Jonathan Javitt, MD, MPH, will join a fireside chat at the upcoming BTIG Virtual Biotechnology Conference on July 29–30, 2025. The session, set for 8:00 a.m. EDT on July 30, will also feature Prof. Samuel Wilkinson, MD, from Yale School of Medicine, and BTIG Research Analyst Dr. Thomas Shrader. The discussion will center on the role of neuroplasticity in treating central nervous system (CNS) disorders, with a particular focus on the use of ketamine and other neuroplastic and psychedelic drugs for conditions such as depression, suicidality, and PTSD.
This event is significant as it sheds light on the potential of innovative treatments for CNS disorders, which affect millions worldwide. NRx Pharmaceuticals is at the forefront of developing therapies based on its NMDA platform, targeting suicidal bipolar depression, chronic pain, and PTSD. The company's investigational drug, NRX-101, has been designated as a Breakthrough Therapy by the FDA for suicidal treatment-resistant bipolar depression and chronic pain, indicating its potential to address unmet medical needs.
Furthermore, NRx Pharmaceuticals is in the process of filing a New Drug Application for NRX-100 (IV ketamine) for the treatment of suicidal depression, leveraging data from clinical trials and French health authorities. The FDA has granted Fast Track Designation for this development, underscoring the urgency and importance of finding effective treatments for acute suicidality. The participation of NRx's CEO in this conference highlights the company's commitment to advancing mental health treatments and the broader implications for the biotechnology and pharmaceutical industries.
